alexa Valsartan Attenuates Cardiotoxicity in Breast Cancer Patients A fter Chemotherapy | OMICS International| Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Review Article   
  • J Cancer Sci Ther/Vol.10.5 105(2018),
  • DOI: 10.4172/1948-5956.1000526

Valsartan Attenuates Cardiotoxicity in Breast Cancer Patients A fter Chemotherapy

Nawal A Al-Hamadi1, Imad Al-Sabri2,5, Amina B Aldujele3, Salam J Al-Fatlawi4 and Zuhair Allebban5*
1Technical Institute of Kufa, , Najaf, Iraq
2Middle Euphrates Cancer Therapy Center, , Najaf, Iraq
3Department of Physiology, College of Medicine, Kufa University, , Najaf, Iraq
4Department of Community Medicine, College of Medicine/Kufa University, , Najaf, Iraq
5Middle Euphrates Unit for Cancer Research, College of Medicine/Kufa University, , Najaf, Iraq
*Corresponding Author : Zuhair Allebban, Middle Euphrates Unit for Cancer Research, College of Medicine/Kufa University, Najaf, Iraq, Tel: +009647804272223, Email: [email protected]

Received Date: Mar 15, 2018 / Accepted Date: May 02, 2018 / Published Date: May 04, 2018

Abstract

Objective: To determine whether valsartan would be useful in attenuating Adriamycin/Cyclophosphamide/ Herceptin (ACH)-induced cardiotoxicity and to assess the role of biomarkers as indicators of cardiotoxicity in patients with breast cancer undergoing cancer therapy.
Background: Valsartan is indicated to reduce the risk of cardiovascular death and hospitalization in patients with chronic heart disease. The administration of cancer drugs, in particular (ACH) is associated with increased risk of cardiotoxicity. The use of herceptin improves survival of women with early-stage positive human epidermal growth factor receptor 2 (HER2) breast cancer but also adds substantially to cost, toxicity, and inconvenience. Little is known about the potential role of valsartan in the prevention of ACH-mediated cardiotoxicity and the predictive role of biomarkers.
Method: A total of 60 untreated HER-2 positive breast cancer patients (ages 24 –70 yr, mean 56 yr) were enrolled in this study and were divided to two groups. Group 1 and 2 had 30 patients each, and group 1 received ACH plus valsartan, group 2 received ACH alone. HER2- positive patients were recruited at the Cancer Therapy Center in Najaf, Iraq. Ejection fraction % (EF%), cardiac Troponin I (cTnI) and high sensitivity C-reactive protein (hsCRP) were measured at baseline and at six months after ACH administration.
Results: Chemotherapy induced significant transient increase in EF%, cTnI, and hsCRP compared to baseline values (P < 0.001). Within one week after valsartan treatment, all these increases returned back to nearly normal levels. Notably, valsartan administration caused a significant decrease in cTnI and hsCRP values compared to baseline (P < 0.001) and it improved EF% value.
Conclusion: This study demonstrated that prophylactic administration of valsartan resulted in the partial attenuation of cardiotoxicity caused by chemotherapy which was characterized by the improvement of EF% and in lowering serum level of cTnI and hsCRP.

Keywords: Valsartan; Cardiotoxicity; Breast cancer; Cardio protection

Citation: A Al-Hamadi N, Al-Sabri I, Aldujele AB, J Al-Fatlawi J, Allebban Z (2018) Valsartan Attenuates Cardiotoxicity in Breast Cancer Patients After Chemotherapy. J Cancer Sci Ther 10: 105-109. Doi: 10.4172/1948-5956.1000526

Copyright: © 2018 Deena HAS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Relevant Topics
Recommended Conferences
Article Usage
  • Total views: 2455
  • [From(publication date): 0-2018 - Dec 07, 2019]
  • Breakdown by view type
  • HTML page views: 2402
  • PDF downloads: 53
Top